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Lupin Peptides Modulate the 
Protein-Protein Interaction of 
PCSK9 with the Low Density 
Lipoprotein Receptor in HepG2 
Cells
Carmen Lammi, Chiara Zanoni, Gilda Aiello, Anna Arnoldi & Giovanni Grazioso
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been recently identified as a new useful 
target for hypercholesterolemia treatment. This work demonstrates that natural peptides, deriving 
from the hydrolysis of lupin protein and absorbable at intestinal level, are able to inhibit the protein-
protein interaction between PCSK9 and the low density lipoprotein receptor (LDLR). In order to sort 
out the best potential inhibitors among these peptides, a refined in silico model of the PCSK9/LDLR 
interaction was developed. Docking, molecular dynamics (MD) simulations and peptide binding energy 
estimations, by MM-GBSA approach, permitted to select the two best candidates among tested 
peptides that were synthesized and evaluated for their inhibitory activity. The most active was P5 that 
induced a concentration dependent inhibition of the PCSK9-LDLR binding, with an IC50 value equal 
to 1.6 ± 0.33 μM. Tested at a 10 μM concentration, this peptide increased by 66 ± 21.4% the ability of 
HepG2 cells to take up LDL from the extracellular environment.
An increased level of low-density lipoproteins (LDL) predisposes to the development of cardiovascular disease 
(CVD) and stroke. Currently, the main agents for lowering LDL levels are statins. They reduce the regulatory pool 
of intracellular cholesterol by competitively inhibiting HMGCoAR, the rate-limiting enzyme of endogenous cho-
lesterol biosynthesis. This in turn activates the LDL receptor (LDLR) transcription, a process under the control of 
sterol regulatory element binding protein 2 (SREBP-2)1,2. The statin cholesterol-lowering action has been consist-
ently shown to translate into fewer cardiovascular events3–5. Nevertheless, residual risk persists in a large portion 
of statin-treated individuals, owing to either inability to achieve desirable LDL levels6,7 or presence of other traits 
predisposing to CVD8,9. Moreover, intolerance to statins produces numerous side effects, such as myopathy with 
a spectrum of consequences ranging from myalgia to rhabdomyolysis10. For the treatment of these individuals, it 
is thus advisable to use alternative or adjunctive therapies. In this context, proprotein convertase subtilisin/kexin 
type 9 (PCSK9) has been recently identified as a new useful target for hypercholesterolemia treatment11.
The human 22-kb gene PCSK9 is located on the small arm of chromosome 1p32 and contains 12 exons and 11 
introns11. The gene encodes a 692-residue extracellular protein named PCSK9 that is expressed primarily in liver, 
kidney, and intestine12 and plays an important role in regulating the degradation of hepatic LDLR13,14. Notably, 
since PCSK9 and LDLR are co-regulated by SREBP-21, increased PCSK9 expression in response to statin-induced 
cellular cholesterol depletion may limit the efficacy of statin treatment15,16. The development of therapies that 
inhibit PCSK9 function holds promise for improved management of hypercholesterolemia and CVD risk. In 
particular, evidence supports the direct binding of secreted PCSK9 to the LDLR, resulting in the receptor degra-
dation17,18. The PCSK9 binding site in the LDLR is located at the first epidermal growth factor-like repeat (EGF-A) 
of the extracellular domain13 and this binding is required for LDLR degradation.
In light of these observations and the fact that circulating PCSK9 may cause the degradation of hepatic LDLR, 
this protein is considered an attractive target for LDL-cholesterol lowering drugs. The current inhibitors under 
development are based on different strategies, i.e. monoclonal antibodies (mAbs) (such as evolocumab and 
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alirocumab)19, gene silencing compounds20, and natural product such as berberine21, and peptidomimetics22,23. 
The most investigated strategy advancing to clinical development is the blockade of PCSK9 interaction with 
LDLR via mAbs. In fact, PCSK9 is an ideal antibody target, since it circulates in the blood and has only modest 
binding affinity to cell surface LDLR. Additionally, its main interaction site is an exposed ∼ 500-Å2 slightly convex 
region readily accessible for antibody binding.
The ability of PCSK9 to mediate LDLR degradation involves protein-protein interactions (PPIs) between 
LDLR and the PCSK9 prodomain24, catalytic domain25, and C-terminal Cys-rich domain (CRD)12,26–28. In this 
context, PPIs, which are inherently challenging small molecule targets, have been successfully inhibited by pep-
tides, which can recapitulate key protein contacts29.
Lupin protein consumption provides some health benefits in the area of hypercholesterolemia prevention30. 
Studies in animal models31,32 and in the clinics33,34 have shown that the protein itself is a main hypocholester-
olemic agent. In this scenario, considering that proteins are hydrolyzed in the gastrointestinal apparatus, a recent 
paper35 has demonstrated that tryptic and peptic peptides deriving from lupin protein hydrolysis are able to 
modulate cholesterol metabolism in HepG2 cells by inhibiting HMGCoAR via a statin-like mechanism. Another 
investigation in human Caco-2 cells has provided evidence that at least some of these peptic and tryptic peptides 
may be absorbed in the small intestine, since they are transferred from the apical (AP) to the basolateral (BL) 
compartment in differentiated Caco-2 cells grown in a two-compartment system36. Table 1 shows the sequences 
of the transferred peptides that here will be referred to as “absorbable lupin peptides”. Finally, another study in 
mild hypercholesterolemic subjects has demonstrated that the level of circulating PCSK9 is reduced in a statis-
tically significant way after a 4-week consumption of a lupin protein isolate (30 g protein/day)37. The same paper 
reported also an investigation in human HepG2 cells showing that lupin peptides reduce the synthesis and secre-
tion of mature PCSK9 as well as the level of hepatic nuclear factor 1-alpha (HNF1-alpha)37.
In this context, the present work was aimed at evaluating whether “absorbable lupin peptides” may directly 
inhibit the PCSK9-LDLR PPI. A second objective was to sort out the best potential inhibitors among “absorbable 
peptides” by a computational protocol specifically developed for this goal. Docking, molecular dynamics (MD) 
simulations and peptide binding energy estimations, by MM-GBSA approach, permitted to select the best can-
didates among peptic and tryptic peptides that were synthesized and evaluated for their inhibitory activity of the 
PCSK9-LDLR interaction and subsequent capability of reducing the LDL uptake by HepG2 cells.
Results
Absorbed peptic and tryptic lupin peptides maintain their capacity to interfere with the PCSK9/
LDLR PPI. As already explained in the introduction, peptic peptides (P-tot) and tryptic peptides (T-tot) from 
lupin protein reduce the synthesis and secretion of mature PCSK9 in HepG2 cells37. In parallel, other experi-
ments, performed in Caco-2 cells grown in two-compartment systems, have indicated that some of these peptic 
and tryptic peptides might be absorbed in the small intestine36. Precisely, Caco-2 cells have been incubated for 
4 h in the AP chamber with 500 μ l of a 1.0 μ g/μ l solution of P-tot or T-tot peptides and, at the end of treatment, 
BL solutions (700 μ l) have been collected and absorbed peptic and tryptic peptides identified by HPLC-Chip 
ESI-MS/MS37. The BL solutions were then dried and diluted to 100 μ l to obtain the solutions P-abs and T-abs 
at the concentration of 0.25 and 0.32 μ g/μ l, respectively. Both solutions were used for the present experiments.
The first experiment had the objective of comparing the ability of total and absorbed peptides to inhibit the 
PCSK9-LDLR binding. In vitro experiments were performed using a solid-phase binding assay between recom-
binant His-tagged PCSK9 and recombinant LDLR-AB domain. The results are shown in Fig. 1. P-tot peptides 
reduced the PCSK9-LDLR binding by 22 ± 6.5% and 25 ± 13.7% (p < 0.001) at 1.0 and 2.5 μ g/μ l, respectively 
(Chart 1A), T-tot peptides by 26 ± 3% and 23 ± 2% at 0.5 and 1.0 μ g/μ l, respectively, whereas P-abs peptides 
Peptide Sequence
Uniprot 
Code Protein Source
Proteolytic 
Enzyme
T1 IILGNEDEQEYEEQR Q6EBC1 β 2-conglutin Trypsin
T2 AVNELTFPGSAEDIER Q6EBC1 β 2-conglutin Trypsin
T3 IVEFQSKPNTLILPK Q6EBC1 β 2-conglutin Trypsin
T4 INEGALLLPHYNSK Q6EBC1 β 2-conglutin Trypsin
T5 HSDADYVLVVLNGR Q6EBC1 β 2-conglutin Trypsin
T6 SNEPIYSNK Q6EBC1 β 2-conglutin Trypsin
T9 GQEQSHQDEGVIVR Q53HY0 β 1-conglutin Trypsin
T10 LLGFGINAYENQR Q53HY0 β 1-conglutin Trypsin
T13 LNALEPDNTVQSEAGTIETWNPK Q53I54 α -conglutin Trypsin
T16 QEEQLLEQELENLPR Q333K7 δ -conglutin Trypsin
P1 YEITPDRNPQVQDL Q6EBC1 β 2-conglutin Pepsin
P3 YDFYPSSTKDQQS Q6EBC1 β 2-conglutin Pepsin
P5 LILPKHSDAD Q6EBC1 β 2-conglutin Pepsin
P6 LRIPAGSTSY Q6EBC1 β 2-conglutin Pepsin
P7 LTFPGSAED Q6EBC1 β 2-conglutin Pepsin
Table 1.  Peptides identified in the basolateral compartment of Caco-2 cells grown in two compartment 
systems36.
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(12.5 ng/μ l) and T-abs peptides (16.0 ng/μ l) inhibited the PCSK9-LDLR interaction by 81 ± 7.6% and 58 ± 4.1% 
(p < 0.0001), respectively, versus the untreated sample (Chart 1B).
In silico model of the human PCSK9. The 3D structure of PCSK9 was modeled and refined following the 
procedure described in the “Methods” section. The PCSK9 model (Figs 2 and S1 in the Supporting Information) 
was selected on the basis of the internal Modeller9.1538 and DOPE scoring function results. It was further vali-
dated applying the QMEAN639 algorithm acquiring a score of 0.7. For this scoring function, quality factors may 
fall in the range between 0 and 1, with higher values for better models. However, low percentages of residues were 
in disallowed (0.7%) and generously allowed regions (0.7%) of the Ramachandran plot. Nevertheless, residues, 
whose phi-psi angle values were outside the allowed regions of the plot, belonged to peripheral loops and were 
further equilibrated by means of MD simulations.
At the end of simulations, the thermal stability of the PCSK9 model was ascertained by analyzing the atomic 
fluctuations per residue plotted versus the residue number during the MD simulations. Remarkably, the model 
displayed a good geometrical stability showing a mean RMSF of Cα atoms of 1.21Å (Figure S2). Moreover, resi-
dues displaying the lowest thermal stability of the backbone atoms were those not well-solved by X-ray studies, or 
belonging to loop connecting secondary structures.
In light of these results, this PCSK9 model was chosen as target protein for docking and further employed for 
lupin peptides binding energy calculation, by a MM-GBSA approach.
Figure 1. Effects of peptic and tryptic lupin peptides on the PCSK9-LDLR binding inhibition. (a) In vitro 
screening of the inhibitory activity of total lupin peptides, i.e. P-tot (1.0 and 2.5 μ g/μ l) and T-tot (0.5 and  
1.0 μ g/μ l), on PCSK9-LDLR PPI; and (b) of absorbed lupin peptides, i.e. P-abs and T-abs (diluted 1:20) (b). The 
commercial assay provides a plate pre-coated with a recombinant LDLR-AB domain, which is the PCSK9 
binding site. For screening direct inhibitors of the PCSK9-LDLR interaction, lupin peptides were added to the 
proper amount of His-tagged PCSK9 in each well coated with LDLR-AB domain. Biotinylated anti-His-tag 
monoclonal antibody specifically reacted with recombinant His-tagged PCSK9 trapped with LDLR-AB domain 
immobilized on the microplate surface. The inhibitory effects were analyzed measuring the amount of His-
tagged PCSK9 on the well. In particular, the inhibitory effect, calculated as % PCSK9-LDLR binding inhibition, 
determines a reduction of absorbance measured at 450 nm using the Synergy H1 fluorescent plate reader from 
Biotek versus vehicle control. Data points represent averages ± SEM of three independent experiments in 
duplicate. * * *p < 0.0001 * * p < 0.001 versus C. C, control vehicle.
Figure 2. Representation of the PCSK9 model used for simulations. Water molecules have been omitted for 
sake of clarity.
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The lupin protein models. Investigated lupin peptides belong to the lupin proteins β 1- and β 2-conglutins, 
α -conglutin and δ -conglutin. Their computational models were created by homology modeling techniques fol-
lowing the procedure described in the “Methods” section. The high percentange of sequence homology found 
with the employed templates permitted to achieve models with reasonable quality, additionally supported by 
MD simulations. At the end of simulations, the energy minimized structures of small peptides T1, T2, and T16 
showed helix conformation, T3, T4, T5, T6, and T9 were folded as ramdom coils, P1, P3, P5, P7, T10, and P6 
showed γ -turn conformations, while peptide T13 was shaped as β -hairpin (Fig. 3).
In order to establish which peptides were mainly responsible for the PCSK9/LDLR PPI inhibition, these mod-
els were used for docking calculations into the LDLR anchor domain of PCSK9. The subsequent MD simula-
tions and final MM-GBSA calculations permitted estimating their theoretical binding energy values on PCSK9 
reported in Table 2. The lowest theoretical binding energy values were calculated for T9 and P5, i.e. a tryptic and 
peptic peptide.
For a deep exploration of the potential interactions these peptides create with the biological counterpart, 
we visually inspected by Pymol the PCSK9/T9 complex resulted minimizing a frame of MD simulations in 
which the system showed geometrical stability. This analysis revealed the presence of several polar and van der 
Waals interactions between the peptide and the enzyme counterparts. In particular, T9 is able to create hydro-
gen bonds by Glu3, His6, Gln7, Asp8 and Ile12 with the PCSK9 residues Cys378, Glu195, Asp238, Ser153 and 
Lys243. Moreover, the side chain of Ile12 in T9 is projected in a hydrophobic pocket shaped by Ile161 and Leu158 
Figure 3. Three-dimensional structure of lupin small-peptides at the end of MD simulations and 
subsequent energy minimization. 
Peptide Sequence
ΔGMM-GBSA ± SE 
ΔG = GComplex − (GPCSK9 + GPeptide) [kcal/mol]
T9 GQEQSHQDEGVIVR − 46.1 ± 1.0
T1 IILGNEDEQEYEEQR − 42.0 ± 0.9
P5 LILPKHSDAD − 39.1 ± 0.8
P3 YDFYPSSTKDQQS − 37.4 ± 1.2
T10 LLGFGINAYENQR − 31.1 ± 0.8
T4 INEGALLLPHYNSK − 25.9 ± 1.2
T5 HSDADYVLVVLNGR − 20.0 ± 1.4
T3 IVEFQSKPNTLILPK − 19.7 ± 0.8
P6 LRIPAGSTSY − 16.3 ± 1.1
P1 YEITPDRNPQVQDL − 15.6 ± 0.9
T13 LNALEPDNTVQSEAGTIETWNPK − 10.9 ± 2.7
T2 AVNELTFPGSAEDIER − 8.6 ± 0.5
T6 SNEPIYSNK − 8.1 ± 0.5
P7 LTFPGSAED − 8.2 ± 0.7
T16 QEEQLLEQELENLPR − 4.7 ± 1.4
Table 2.  Results of MM-GBSA calculations on PCSK9/peptide complexes.
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(Fig. 4A). Interestingly, MD simulations suggested that C-terminal Arg14 is immersed in a cavity with variable 
size due to the high conformational mobility of the protein loop formed by sequence from Asp17 to Ser26 (Fig. 5). 
This conformational mobility explains why the same protein portion was not solved by X-ray studies. However, 
by way of our developed model, this area could represent the target for designing new potent ligands or peptides.
On the other hand, P5 produces a hydrogen bond assisted salt bridge by means of C-terminal Asp11 with 
Lys222 of the enzyme, while its Leu1, Leu3, and Ser7 can produce a supplementary hydrogen bond network with 
Lys243, Asp238, and Phe379 of PSCK9, respectively (Fig. 4B).
Isolated lupin peptides inhibit the PCSK9-LDLR binding. In order to assess the efficacy of the bio-
informatics prediction, T9 and P5, the best potential inhibitors among peptic and tryptic peptides identified 
through computational studies, were synthesized and tested for their capacity to inhibit the PCSK9-LDLR bind-
ing. T9 significantly reduced the PCSK9-LDLR binding by 19 ± 8.47%, 33 ± 5.33%, and 53 ± 1.02% (p < 0.05 and 
p < 0.001) at 32, 160, and 320 μ M concentrations, respectively, versus the untreated sample (Fig. 6a). P5 (tested 
in the range 0.001–100 μ M) induced a concentration dependent inhibition of the PCSK9-LDLR binding, with an 
IC50 value equal to 1.6 ± 0.33 μ M (Fig. 6b).
Through the inhibition of PCSK9-LDR PPI, T9 and P5 increase the ability of HepG2 cells to 
uptake LDL from the extracellular environment. For a deeper insight of the activity of T9 and P5, 
the change of the functional capability of HepG2 cells to uptake extracellular LDL was investigated after treat-
ment with these peptides by performing fluorescent-LDL uptake experiments. As shown in Fig. 7, each peptide 
increased the LDL-uptake versus the control in a statistically significant way (p < 0.001). In fact, the treatment 
with P5 (10 μ M) led to an increase of the LDL-uptake by 66 ± 21.4%, whereas that with T9 (100 μ M) increased 
the LDL-uptake by 55 ± 24.4%, versus the untreated sample. Therefore, both P5 and T9 are able to improve the 
HepG2 ability to absorb extracellular LDL, although their potency is very different, being the latter about ten 
times less active than the former.
Figure 4. Docking and MD simulations results for T9 (panel A) and P5 (panel B). T9 and P5 are represented 
as magenta and green stick models, respectively. The showed conformations of T9 and P5 were retrieved 
minimizing MD frames in which the systems displayed geometrical stability. PCSK9 is displayed as cyan thin 
stick model and only residues within a radius of 4 Å from docked peptides are shown and labeled in the pictures. 
PCSK9 surface is colored according to the atoms electrostatic charges (blue for positive and red for negative), 
suitably calculated by Pymol tools.
Figure 5. Representation of PCSK9 trajectory frames acquired during MD simulations and selected 
for MM-GBSA analysis. Different conformations of T9 are represented as thin stick models while PCSK9 is 
represented as cartoon. Arrows indicates the most flexible portion of the enzyme (From Asp17 to Ser26) and the 
localization of the site where the EGF-A domain of LDLR can be anchored in physiological conditions.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:29931 | DOI: 10.1038/srep29931
Recently, we have demonstrated that HepG2 cells secrete 141 ng/ml of mature PCSK9 in physiological condi-
tions37. These results indicate that the capacity of T9 and P5 to impair the binding of secreted PCSK9 to the LDLR 
stabilizes the active LDLR on cell membrane, leading to an improved ability of hepatic cells to uptake extracellular 
LDL with a final hypocholesterolemic effect.
Quantification of P5 in the sample P-abs. The excellent activity of P5 suggested its quantification in 
the P-abs sample. This was obtained by HPLC-MS/MS by building the calibration curve injecting the synthetic 
standard: the P5 concentration in the P-abs solution was calculated to be 28.64 ± 0.43 ng/μ l, corresponding to 
11.5% of the total peptic peptides absorbed by CaCo-2 cells.
Discussion
The discovery of PCSK9 in 200340 opened a new scenario in the lipid field. In fact, whereas previously statins 
were considered the best hypocholesterolemic drugs, subsequently PCSK9 inhibitors became another therapeutic 
option. In this context, numerous studies have focused their attention on mAbs19, gene silencing compounds20, 
Figure 6. Peptides T9 and P5 inhibit the PCSK9-LDLR binding. Inhibitory effects of (a) T9 (32, 160, and 
320 μ M) and (b) P5 (0.001–100 μ M) on the PCSK9-LDLR PPI in vitro. The employed assay provides a plate pre-
coated with a recombinant LDLR-AB domain, which is the PCSK9 binding site. For screening, the peptides were 
added to proper amount of His-tagged PCSK9 in each well coated with LDLR-AB domain. Biotinylated anti-
His-tag monoclonal antibody specifically reacts with recombinant His-tagged PCSK9 trapped with LDLR-AB 
domain immobilized on the microplate surface. The inhibitory effects of T9 and P5 were analyzed measuring 
the amount of His-tagged PCSK9 on the well. The T9 and P5 inhibition, calculated as % PCSK9-LDLR binding 
inhibition, was measured from the absorbance reduction at 450 nm, using the Synergy H1 fluorescent plate 
reader (Biotek) versus vehicle (control). P5 showed a concentration-response behavior, with an IC50 equal to 
1.6 μ M. Data points represent averages ± SEM of three independent experiments in duplicate. * p < 0.05  
* * P < 0.001 versus C. C, vehicle.
Figure 7. Fluorescent LDL-uptake assay after lupin peptide treatments of HepG2. Cells (3 × 104) were 
treated with T9 (100 μ M) and P5 (10 μ M) for 24 h. LDL-Dylight 549 (10 μ g/ml) was incubated for an additional 
2 h. Excess LDL-Dylight 549 was removed and cells were washed 2 times with PBS. Specific fluorescent LDL-
uptake signal was analyzed by Synergy H1 (Biotek). Data points represent averages ± SEM of three independent 
experiments in triplicate. * * p< 0.001 versus C. C, vehicle.
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peptidomimetics22, and berberine21. At the best of our knowledge, instead, this is the first paper providing exper-
imental evidence that some peptides deriving from food protein hydrolysis may function as effective inhibitors 
of the PCSK9-LDLR PPI.
Our investigation was focused on lupin protein, since a very recent paper has shown that in hypercholes-
terolemic subjects, who had consumed dietary bars containing lupin protein for a month, the total cholesterol 
decrease was accompanied by a parallel decrement of circulating PCSK937. Other relevant evidences available 
before starting the present investigation were the following: 1) peptic and tryptic peptides, obtained digesting a 
total protein extract from lupin seed with pepsin and trypsin are able to inhibit the interaction of PCSK9 with 
the LDLR in an in vitro system37; 2) some of these peptides, identified by HPLC-ESI-MS/MS, are absorbed in a 
Caco-2 model of the small intestine36.
These evidences prompted us to investigate whether the absorbed peptides (P-abs and T-abs) maintained the 
inhibitory activity of P-tot and T-tot, i.e. whether at least some bioactive peptides had been absorbed. In this con-
text, the demonstration that the capacity of these peptides to inhibit the PCSK9/LDLR interaction is not impaired 
by the absorption is certainly a main achievement of this work. The fact that at least some bioactive peptides are 
absorbed is not obvious, considering that only part of the original peptides were absorbed in the Caco-2 model36, 
since at the end of treatment some were still detectable only in the AP compartment and other disappeared in 
both compartments owing to metabolic degradation.
A natural development of this research was the application of in silico tools for potentially sorting out the most 
bioactive peptides. The first step was the modeling a refined human PCSK9 3D-structure, starting from X-ray 
available literature data23. Afterward, the peptides 3D-structures were calculated and refined starting from the 
structures of the proteins to whom they belong. Their conformations are very variable, since three have helix con-
formations, five γ -coil conformations, one β -hairpin conformation, and six are random coils. Finally, the docking 
study permitted to estimate their theoretical binding energy values on PCSK9 and therefore to get a classification 
in which T9 was the best candidate among tryptic peptides and P5 the best among peptic peptides. Interestingly, 
both derive from the hydrolysis of lupin β -conglutin, a 7S vicilin-like storage globulin. T9 consists of 14 amino 
acidic residues, whereas P5 of 10 amino acidic residues.
The following experiments, performed on the synthetic peptides, confirmed that indeed they are able to impair 
the interaction of PCSK9 with the LDLR. P5 resulted to be the most active, with an IC50 value equal to 1.6 μ M, 
whereas T9 was much less active, since its IC50 falls around 320 μ M. The experiment on the ability of HepG2 cells to 
uptake LDL from the extracellular environment confirmed the better efficacy of P5. This is not completely in agree-
ment with the MM-GBSA calculations, which predicted a higher affinity for T9 than P5. This inaccuracy might be due 
to the omitted estimation of the entropic contribution to the binding free energy of peptides. In practice, the entropic 
contribution to the binding free energy could be higher than that of T9, explaining the discrepancy between the cal-
culation and the experimental results. Unfortunately, computational techniques do not permit to get an accurate pre-
diction of the entropic contribution value yet. Available tools are computationally very demanding, requiring highly 
energy minimized structures for “normal mode” analysis, or large amount of conformations for “quasi-harmonic” 
analysis41–43. In any case, our calculations permitted to sort out at least one lupin peptide with a great potential interest 
as inhibitor of the interaction of PCSK9 with the LDLR, owing to the very low IC50 value equal to 1.6 μ M.
It is useful to observe that Pep2-8 (Ac-TVFTSWEEYLDWV-amide), the best inhibitor singled out by Zhang 
and coworkers in a recent paper23, has an IC50 value equal to 0.81 ± 0.08 μ M, i.e. only slightly better than that of 
P5. Interestingly, Pep2-8 contains 13 amino acid residues and its C-terminal truncated analogues loose activity, 
whereas P5 contains only 10 residues. P5 is thus one of the shortest peptides ever described in literature endowed 
with this specific activity.
The superimposition of PCSK9/P5 complex, resulted by minimizing a frame of MD simulations in which 
the system showed geometrical stability, with the X-ray structure of PCSK9/Pep2-8 (PDB code 4NMX) revealed 
that the α -helix of Pep2-8 was found in proximity of the PCSK9 N-terminal domain (Ser153). The Leu-Ile-Leu 
sequence of P5 was able to occupy a basin shaped by Ile154, Leu158 and Lys243 (Fig. 8A) while the side chain 
of P5 Pro4 was perfectly aligned on the one belonging to Pep2-8 Trp6, and both residues occupied the pocket 
sized by PCSK9 Phe379, Ala239, and Asp238. Additionally, the side chain of P5 His6 was located into the PCSK9 
area close to Ile369, as the side chain of Pep2-8 Phe3. This observations may open the way to the design of 
new and more potent derivatives (small molecules or peptides), able to occupy the Ile154, Leu158 and Lys243 
solvent-exposed pocket. As well, P5 sequence could be optimized by performing a virtual alanine-scanning aim-
ing to predict which residues efficiently contribute to the binding of the peptide on PCSK9. Then, residues could 
be suitably mutated into new terms showing higher complementarity with the PCSK9 active site.
Remarkably, also the superimposition of P5 on the EGF-A domain of LDLR co-crystallized with PCSK9 (PDB 
code 4NE9) showed a good overlapping. In fact, Pro3 and His6 of P5 were able to mimic very well the interactions 
played by the side chains of EGF-A Leu298 and Asn301 on PCSK9. Additionally, the side chain of P5 Ser7 was 
in line with the oxygen atom of EGF-A Cys308, creating a hydrogen bond with the backbone of PCSK9 Phe379. 
Taking into account these considerations, it is possible to affirm that P5 is able to mimic some key interactions 
played by Pep2-8 and EGF-A on PCSK9. This may explain the efficient biological activity displayed by P5.
Nevertheless, the real conformations of the PCSK9/small peptides complexes could be different from those 
here described. The reasons of this uncertainty are due to the use of molecular mechanics methods, the limited 
sampling of MD simulations, and the creation of homology models of the lupin proteins. However, we have 
applied well-validated molecular modeling procedures in order to decrease as possible the degree of uncertainty.
Finally, it is important to recapitulate the very original approach of our investigation:
(1) detection of a PCSK9 decrease in the plasma of hypercholesterolemic subjects at the end of a dietary interven-
tion study based on dietary bars containing lupin protein;
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(2) demonstration that lupin peptides reduce the PCSK9 synthesis and secretion in HepG2 cells;
(3) identification of lupin peptides which are absorbed in Caco-2 cells;
(4) demonstration that they retain the original capacity of impairing the PCSK9/LDLR interaction;
(5) classification of their potential activity by docking studies with the PCSK9-LDLR complex and selection of 
the best candidates;
(6) identification of the very potent peptide P5.
Owing to the unusual process of the identification and its original sequence, indeed P5 may be a promising 
candidate for designing new potent inhibitors of the PCSK9/LDLR PPI. In conclusion, this is the first experimen-
tal evidence that a peptide deriving from a plant protein has this specific biological activity.
Methods
Preparation of the pepsin and trypsin peptide mixtures. The peptic (P-tot) and tryptic (T-tot) 
hydrolyzates from lupin protein are the same used in a previous paper, in which their capability to modulate cho-
lesterol metabolism in HepG2 cells was investigated35. The procedure for protein extraction from Lupinus albus 
(cultivar Ares) seeds, the conditions of enzymatic hydrolysis, and the final composition of the resulting peptide 
mixtures are reported in detail in the same paper. In the tryptic sample, 12 peptides were assigned to L. albus 
vicilin-like protein (Q53HY0), 10 peptides to L. albus beta‐conglutin precursor (Q6EBC1), 4 peptides to Lupinus 
angustifolius conglutin beta (B0YJF8)], 4 peptides to L. angustifolius conglutin-beta (Q53I55)], and 2 to L. albus 
conglutin-delta seed storage protein precursor (Q99235). In the peptic hydrolysate, 21 peptides were assigned to 
L. albus vicilin-like protein (Q53HY0), 18 peptides to L. albus beta‐conglutin (Q6EBC1), 7 peptides to L. angus-
tifolius conglutin-alpha 3 (F5B8V8], and 8 peptides to L. albus conglutin-gamma (Q9FSH9). These mixtures 
were submitted to absorption experiments in Caco-2 cells grown in two-compartment trans-well systems36. The 
absorbed peptic (P-abs) and tryptic peptides (T-abs), i.e. those transferred in the basolateral compartments, are 
shown in Table 1. The details for the preparation and quantification of the peptides and the analytical procedure 
for their identification based on mass spectrometry are described in detail in that paper36.
In vitro PCSK9-LDLR binding assay. P-tot peptides (1.0 and 2.5 μ g/μ l), T-tot peptides (0.5 and 1.0 μ g/μ l), 
P-abs (12.5 ng/μ l) and T-abs peptides (16.0 ng/μ l) were tested using the in vitro PCSK9-LDLR binding assay 
(CycLex Co., Nagano, Japan) following the manufacture instructions. Briefly, plates are pre-coated with a recom-
binant LDLR-AB domain, which contains the binding site for PCSK9. Before starting the assay, tested peptides 
and/or the vehicle were diluted in reaction buffer and added in microcentrifuge tubes. Afterwards, the reaction 
mixtures were added in each well of the microplate and the reaction was started by adding His-tagged PCSK9 
wild type solution (3 μ l). The microplate was allowed to incubate for 2 h at room temperature (RT) shaking at 
300 rpm on an orbital microplate shaker. Subsequently, wells were washed 4 times with wash buffer. After the 
last wash, the biotinylated anti-His-tag monoclonal antibody (100 μ l) was added and incubated at RT for 1 h 
shaking at 300 rpm. After incubation, wells were washed for 4 times with wash buffer. After the last wash, 100 μ l 
of HRP-conjugated streptavidin were added and the plate was incubated for 20 min at RT. After incubation, wells 
were washed 4 times with wash buffer. Finally, the substrate reagent (tetra-methylbenzidine) was added and 
the plate was incubated for 10 min at RT shaking at ca. 300 rpm. The reaction was stopped with 2.0 N sulfuric 
acid and the absorbance at 450 nm was measured using the Synergy H1 fluorescent plate reader (Biotek, Bad 
Friedrichshall, Germany).
The human PCSK9 model. Molecular modeling studies started retrieving the PCSK9/LDLR complex (PDB 
code 4NE9, resolution 2.6 Å) from Protein Data Bank (PDB)44. The unsolved regions of PCSK9 were modeled by 
Modeller9.1538, taking into account also the crystal structure stored with PDB code 3P5C45. This structure has 
reduced amount of unsolved regions but lower resolution (4.2 Å). One hundred models were created: the most 
Figure 8. (A) Superimposition of PCSK9/P5 and PCSK9/Pep2-8 (PDB code 4NMX) complexes. P5 is 
represented as green stick and cartoon models, whereas Pep2-8 is colored in yellow. (B) Superimposition of 
PCSK9/P5 and PCSK9/EGF-A (residues from Ly289 to Pro319, PDB code 4NE9) complexes. P5 remains 
represented as green stick and cartoon models, whereas EGF-A domain of LDLR is colored magenta. Both 
panels show the PCSK9 surface colored according to the atoms electrostatic charges (blue for positive and red 
for negative), suitably calculated by Pymol tools.
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accurate one was chosen considering the results of the DOPE scoring function and the quality factors acquired 
by means of Procheck46 and QMEAN6 score, provided by SWISSMODEL server/Protein Structure & Model 
Assessment Tools39.
Furthermore, in order to better refine the rough PCSK9 model, energy minimization and MD simulations 
were performed. The model was solvated with almost 25,000 water molecules (Amber12 package)47, creating a 
system composed by more than 79,000 atoms. FF0348 version of the AMBER force field was used for the protein, 
while the TIP3P model49 was used to explicitly represent water molecules. Van der Waals and short-range electro-
static interactions were estimated within 12 Å cutoff, while the long-range electrostatic interactions were included 
by using the particle mesh Ewald method50.
Bonds involving hydrogen atoms were constrained using the SHAKE algorithm51, enabling the use of a 2 fs 
time step. After a preliminary minimization run, where only the solvent was optimized, the model was geomet-
rically optimized starting from the side chain conformations and then continuing with the whole protein. Prior 
to starting the MD simulations, the system was equilibrated for 40 ps at 300 K in isocore conditions (NVT), then 
isothermal-isobaric ensemble were carried out at 300 K. Berendsen’s coupling algorithm52 was active to maintain 
the pressure (1 atm) for both solvent and solute molecule, while the coupling constant was set to 1.5 ps. Periodic 
boundary conditions were applied in the MD simulations and, in the production run, 100 ns of MD simulations 
were performed by pmemd.cuda module of AMBER12. Then, the acquired MD trajectory was examined by visual 
inspection with VMD53, ensuring that the thermalization did not cause any structural distortion.
Models of small peptides. The lupin globulins β 1- and β 2-conglutins are the major sources of small pep-
tides considered in this study, i.e. T1–T6, T9–T10, P1, P3, P5, P6-P7 (Table 1). In order to build their compu-
tational models, it was initially decided to create the 3D structure of complete β 1- and β 2-conglutins. Then, the 
portions matching the sequence of the target small-peptides were extracted and singularly geometrically refined 
by MD simulations in a water environment.
Unfortunately, structural information of both β -conglutins are not available in Protein Data Bank, thus 
homology-modeling techniques were applied to build these models. In particular, the SWISSMODEL server54 
found the optimal templates for the target sequences and Modeller9.1538 was used to build the final 3D mod-
els. Two templates, soybean β -conglycinin (PDB code 1UIK, 56.4% identity, 85.6% similarity)55 and AraH1, a 
vicilin-like protein from peanut (PDB code 3S7E56, 52.9% identity and 83.4% similarity, Figures S3 and S4 in 
Supporting materials) were employed for the construction of the β 2-conglutin models. Whereas, the β 1-conglutin 
model was built by homology modeling using the previously developed β 2-conglutin model, due to their high 
sequence homology (94.3% sequence identity and 97.9% similarity).
T13, derived from α -conglutin, was built by the similar approach using as template soybean proglycinin 
(59.1% sequence identity and 83.0% similarity, Figure S5 in Supporting materials), for which three crystal struc-
tures (PDB codes 1UCX57, 1FXZ58 and 3KSC59) were available.
Finally, T16, deriving from δ -conglutin, was built using peanuts AraH2 protein (PDB code 3OB4) as template 
(50.0% sequence identity and 87.5% similarity, Figure S6 in Supporting materials).
All sequence alignments were performed by BLOSUM 250 matrix and LALIGN server60, then Modeller9.1538 
built one hundred models of each target protein. The best models were chosen accordingly with their quality 
parameters (DOPE scoring function and PROCHECK46).
Each model was then solvated, computationally parameterized as previously described for PCSK9, energy 
minimized, and submitted to MD simulations (20 ns), in order to geometrically equilibrate the systems. Finally, 
portions matching with each peptide were extracted and the suitable models were optimized again in water envi-
ronment by additional 20 ns of MD simulations.
Docking, MD simulations and peptide binding energy estimations. In order to establish which 
lupin peptides were the main responsible for the biological activity on PCSK9, their theoretical binding energies 
needed to be calculated. To this aim, docking studies, MD simulations and Molecular Mechanics-Generalized 
Born Surface Area (MM-GBSA) calculations were performed41. Docking of proteins is still challenging, due to 
their high flexibility. Several algorithms, also available by web-server, have been developed to this aim. For exam-
ple, pepATTRACT61 and CABS-dock server62, based on a coarse-grained protein models, have been designed 
to efficiently take into account the protein conformational changes, obtaining satisfactory results. Additionally, 
FlexPepDock63,64 or HADDOCK65 are tools capable to refine the docking poses produced by different algorithms, 
in the respect of sets of experimental data. Nevertheless, also small molecules docking programs are valid alter-
native to these algorithms66. Here, we performed all-atoms docking calculations by GOLD5.2 algorithm67, taking 
into account all degrees of freedom of small peptides. Further MD simulations permitted both the optimization 
of the small peptide geometries into the PCSK9 EGF-A binding domain, and the acquiring of the MD trajectories 
useful for the binding free energy estimation, by MM-GBSA approach. In the docking calculations, fifty poses 
were generated for each peptide in the binding site recognized by the presence of the EGF-A domain of LDLR in 
the PCSK9 crystal structure (12 Å around PCSK9 Phe379). The conformations of the lupin small peptides resulted 
minimizing the last frame of MD simulations were used for docking. Peptides were docked considering all the 
degrees of freedom for the side chains and backbone torsion angles. At variance, peptide bonds were retained in 
“s-trans” conformations and the presence of internal H-bonds were detected and conserved during the docking 
calculations. PCSK9 were considered frozen and at the end of calculations, all generated poses were clustered by 
the complete-linkage method68. This is an agglomerative hierarchical clustering algorithm in which, initially, each 
element is located in a different singleton cluster. Clusters are then combined into larger ones until all elements 
are in the same cluster.
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The clusters of solutions displaying RMSD values within 4 Å were selected and ranked depending on the 
ChemPLP69 score acquired by the representative solution, the one with the highest score in each cluster. Due to 
the very high degrees of freedom of each peptide, numerous clusters were created, showing similar scores but 
different binding modes. For this reason, the first three clusters of each peptides were visually inspected by Pymol 
and superimposed on the available X-ray structures of PCSK9 with EGF-A and Pep2-8 peptides. Then, the dock-
ing solutions of lupin peptides able to mimic their structural features were selected for further studies.
Accordingly, the obtained PCSK9/small peptide complexes were submitted to MD simulations, adopting the 
computational parameters previously described for PCSK9 model. Here, in the production runs, 50 ns of MD 
simulations for each system were recorded, permitting to acquire the trajectories useful for the subsequent bind-
ing energy calculations by the “single trajectory” protocol of the MM-GBSA approach70. The main advantage of 
this computational protocol is the use of an ensemble of structures (snapshots) accounting for more than one 
possible conformation of the protein/peptide complex. Therefore, the MM-GBSA methodology was not sensitive 
to the atomic details of single representative conformations obtained by docking methods. Furthermore, through 
the application of the conformational sampling to generate thermodynamic averages, one can also better simulate 
the protein-protein, or the protein-ligand, reciprocal adaptation, a phenomenon commonly referred to as the 
induced-fit71.
In this case, snapshots were extracted from each trajectory when the systems reached the geometrical stability, 
i.e. the RMSD vs time plot reached a plateau and the exponential tendency line of the peptide Caplha RMSF did 
not show any inclination (Figure S7). Twenty snapshots were regularly extracted to ensure the lowest standard 
error in the free energy estimation and the lowest calculation time. The time intervals for the extraction were 
chosen dividing by 20 the number of frames in which the systems showed the geometrical stability. MM-GBSA 
calculations were performed by MM-PBSA.py module of Amber12, keeping parameters in the default values. 
Nevertheless, this evaluation did not take into account the entropic contributions to the final binding free energy 
values, but only the enthalpy and desolvation free energy contributions. Thus, the obtained results should be 
considered as an attempt to estimate the binding energy values (Δ G* ) of the lupin peptides under investigation72.
Synthetic peptides. T9 GQEQSHQDEGVIVR and P5 LILPKHSDAD were synthesized by the company 
PRIMM (Milan, Italy). They were > 95% pure by HPLC.
In vitro PCSK9-LDLR binding assay of T9 and P5. Synthetic peptides, i.e. T9 (32–320 μ M) and P5 
(0.001–100 μ M), were tested using the in vitro PCSK9-LDLR binding assay (CycLex Co., Nagano, Japan) follow-
ing the manufacture instructions as reported above. The absorbance at 450 nm was measured using the Synergy 
H1 fluorescent plate reader (Biotek, Bad Friedrichshall, Germany). In particular, for the in vitro screening of the 
synthetic PCSK9-LDLR inhibitors, T9 and P5, at different concentrations, were added to the appropriate amount 
of His-tagged PCSK9 in the wells that had been coated with recombinant LDLR-AB domain in a similar fashion 
as described above, followed by evaluation of inhibitory effect on PCSK9-LDLR interaction by measuring the 
amount of His-tagged PCSK9 on the wells which is correlated to the absorbance signals at 450 nm, which were 
measured using the Synergy H1 fluorescent plate reader (Biotek, Bad Friedrichshall, Germany).
Cell line culture. The HepG2 cell line was bought from ATCC (HB-8065, ATCC from LGC Standards, Milan, 
Italy). HepG2 cells were cultured in DMEM high glucose with stable L-glutamine supplemented with 10% FBS, 
100 U/ml penicillin, 100 μ g/ml streptomycin (complete growth medium) and incubated at 37 °C under 5% CO2 
atmosphere. HepG2 cells were used for no more than 20 passages after thawing, because the increase of the num-
ber of passages may change the cell characteristics and impair assay results.
Fluorescent LDL uptake cell based assay. HepG2 cells (3 × 104/well) were seeded in 96-well plates and 
kept in complete growth medium for 2 d before treatment. The third day, they were treated with T9 (160 and 320 μ M) 
or P5 (10 μ M), or vehicle (H2O) for 24 h. At the end of the treatment, the culture medium was replaced with 50 μ l/
well LDL-DyLight™ 550 working solution (Cayman Chemical Company, Ann Arbor, MI, US). The cells were addi-
tionally incubated for 2 h at 37 °C and then the culture medium was aspirated and replaced with PBS (100 μ l/well). 
The degree of LDL uptake was measured using the Synergy H1 fluorescent plate reader from Biotek (excitation 
and emission wavelengths 540 and 570 nm, respectively).
Statistical analysis of biological assays. Data are presented as mean ± standard error using GraphPad 
Prism 6 (GraphPad, La Jolla, CA, USA). Statistical analyses were carried out by one-way ANOVA followed by 
Dunnett’s test. P-values < 0.05 were considered to be significant.
Quantification by mass spectrometry of peptide P5 in P-abs. The LC-M analysis was carried out 
in positive ionization mode on a SL series Ion Trap mass spectrometer equipped with a nESI source interfaced 
with a HPLC-Chip Cube source (Agilent Technologies, Palo Alto, CA, USA). The chromatographic separation 
was performed on a LC-chip containing a 40 nL enrichment column (Zorbax 300SB-C18, 5 μ m pore size), a 
43 mm × 75 μ m analytical column packed (Zorbax 300SB-C18, 5 μ m pore size). The sample (1 μ L) was loaded 
onto the enrichment column at a flow rate 4 μ L/min for 2 min using isocratic 100% C solvent phase (99% water, 
1% ACN and 0.1% FA). After cleanup, the chip valve was switched to separation and trapped peptides were eluted 
into the mass spectrometer at the constant flow rate of 0.3 μ L/min using H2O, 0.1% HCOOH (A) and ACN, 
0.1% HCOOH (B) as elution solvent. The nano-pump gradient used was the following: 3% solvent B (0 min), 
30% solvent B (0–4 min) and back to 3% in 1 min. A column re-equilibration time of 2 min was used after each 
analysis. The nano-ESI source operated under the following conditions: drying gas temperature 300 °C, flow rate 
3 L/min (nitrogen), capillary voltage 1950 V, with endplate offset − 500V. The LC-MS/MS analysis, under pseudo 
MRM condition, were carried out monitoring one diagnostic transition m/z 554.8 → m/z 770.0, selecting the 
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most intense y-fragment ion, corresponding to y7. The QuantAnalysis data package was used to build calibration 
curves by integrating at each calibration level (CL) the area of the m/z 770.0, the main product ion of double 
charged m/z 554.8 precursor ion. The concentration was estimated using an external calibration curve built from 
standard solution of peptide. The concentration of analyte in the standard solution ranged from 5 to 50 ng/μ L. 
The accuracy test calculated preparing one spiked sample at 8 ng/μ l was higher than 110%. The repeatability 
of the method was obtained by injecting the sample and the calibration levels three times each. The amount of 
LILPKHSDAD in P-abs was 28.64 ± 0.43 ng/μ l. The relative standard deviation (RSD %) value resulted 1.5%. The 
limit of detection (LOD) and the limit of quantification (LOQ) were calculated by applying the Eqs. SLOD = SRB + 3 σ RB 
and SLOQ = SRB + 10 σ RB, respectively, following the directives of IUPAC and American Chemical Society’s 
Committee in Environmental Analytical Chemistry, where SLOD is the signal at the limit of detection, SLOQ is the 
limit of quantification, SRB is the signal of blank control, and σ RB is the standard deviation. The calculated values 
of LOQ and LOD, corresponding to 3.92 and 3.71 ng/μ l, respectively, confirm the reliability of the quantification 
method.
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